Dr Jitendra Singh Inaugurates Recombinant Cell Facility At BRIC-RGCB
ECONOMY & POLICY

Dr Jitendra Singh Inaugurates Recombinant Cell Facility At BRIC-RGCB

Union Minister Dr Jitendra Singh inaugurated the Central Facility for Recombinant Cells and Sensors at BRIC-Rajiv Gandhi Centre for Biotechnology in Thiruvananthapuram, Keralam, noting the facility will accelerate target-specific drug discovery and support medical and agricultural genomics. The minister also announced the foundation stone for a dedicated GMP facility and released a book by Professor V.P.N. Nampoori. The new facility was developed with investment of Rs 60 crores, equivalent to 600 million (600 mn) and is intended to serve academia, industry and healthcare innovators.

He outlined a vision for a bio-driven economy supported by the BioE3 Policy, which aims to align economy, environment and employment to boost biomanufacturing. He cited that India’s bioeconomy has grown 16-fold in the past decade from 10 billion US dollars (10 bn US dollars) to nearly 166 billion US dollars (166 bn US dollars) and is aiming for 300 billion US dollars (300 bn US dollars). The policy emphasis is intended to anticipate and enable a shift towards large-scale biomanufacturing and bio-based industries.

He highlighted growth in entrepreneurship with the number of biotechnology start-ups rising from about 50 to 70 in 2014 to over 11,000, reflecting an expanding innovation ecosystem supported by policy reforms and funding for deep-tech start-ups. The Department of Biotechnology has funded the new recombinant cell facility through long-term programmes. He emphasised the rising burden of non-communicable diseases and the institute's research in cancer biology, preventive healthcare and HPV vaccination evidence.

He announced that the GMP facility will support pre-commercial production of biologics and cell-based therapies, including CAR-T therapy, and will operate on a pay-and-use basis for biotech industries with implementation in two phases and total DBT investment of Rs 80 crores, equivalent to 800 million (800 mn). He called for deeper collaboration among research institutions, private industry and emerging sectors such as nuclear medicine and deep-ocean research, encouraging coastal states to align biotechnology with national missions. He urged young researchers to utilise the expanding ecosystem and assured continued government support for innovation and interdisciplinary collaboration.

Union Minister Dr Jitendra Singh inaugurated the Central Facility for Recombinant Cells and Sensors at BRIC-Rajiv Gandhi Centre for Biotechnology in Thiruvananthapuram, Keralam, noting the facility will accelerate target-specific drug discovery and support medical and agricultural genomics. The minister also announced the foundation stone for a dedicated GMP facility and released a book by Professor V.P.N. Nampoori. The new facility was developed with investment of Rs 60 crores, equivalent to 600 million (600 mn) and is intended to serve academia, industry and healthcare innovators. He outlined a vision for a bio-driven economy supported by the BioE3 Policy, which aims to align economy, environment and employment to boost biomanufacturing. He cited that India’s bioeconomy has grown 16-fold in the past decade from 10 billion US dollars (10 bn US dollars) to nearly 166 billion US dollars (166 bn US dollars) and is aiming for 300 billion US dollars (300 bn US dollars). The policy emphasis is intended to anticipate and enable a shift towards large-scale biomanufacturing and bio-based industries. He highlighted growth in entrepreneurship with the number of biotechnology start-ups rising from about 50 to 70 in 2014 to over 11,000, reflecting an expanding innovation ecosystem supported by policy reforms and funding for deep-tech start-ups. The Department of Biotechnology has funded the new recombinant cell facility through long-term programmes. He emphasised the rising burden of non-communicable diseases and the institute's research in cancer biology, preventive healthcare and HPV vaccination evidence. He announced that the GMP facility will support pre-commercial production of biologics and cell-based therapies, including CAR-T therapy, and will operate on a pay-and-use basis for biotech industries with implementation in two phases and total DBT investment of Rs 80 crores, equivalent to 800 million (800 mn). He called for deeper collaboration among research institutions, private industry and emerging sectors such as nuclear medicine and deep-ocean research, encouraging coastal states to align biotechnology with national missions. He urged young researchers to utilise the expanding ecosystem and assured continued government support for innovation and interdisciplinary collaboration.

Next Story
Infrastructure Urban

Panasonic Showcases Connected Display Solutions

Panasonic Life Solutions India showcased its integrated display, projection, broadcast and communication technologies at Panasonic Tech Summit 2026 in New Delhi. Hosted through its System Solutions Division, the two-day event highlighted connected technology solutions for education, healthcare, retail, transportation, corporate offices and entertainment.The summit, themed ‘Turning Technology into Value’, featured experience-led zones covering QSR, retail, transit, corporate offices, healthcare, education, security, projection, home theatre and professional displays. Panasonic also introduc..

Next Story
Infrastructure Transport

Kapsch to Deliver India’s First C-ITS Project

"Kapsch TrafficCom will deliver India’s first Cooperative Intelligent Transport Systems project on a key expressway near New Delhi. The project will be implemented with Superwave Communication And Infrasolution Limited to demonstrate how connected mobility can improve road safety and traffic efficiency.The pilot will use real-time connectivity and AI-enabled situational awareness to support road users, especially in high-risk areas such as temporary work zones. Drivers will receive alerts on roadworks, maintenance vehicles, hazardous locations, traffic queues and temporary virtual signage di..

Next Story
Infrastructure Urban

Eurobond Net Profit Rises 44 Per Cent

Euro Panel Products, the parent company of Eurobond, reported a 44.13 per cent year-on-year rise in net profit for FY25–26. The company’s revenue from operations grew 18.91 per cent to Rs 503.20 crore, compared to Rs 423.18 crore in the previous financial year.The company’s full-year EBITDA stood at Rs 56.67 crore, marking a 31.82 per cent increase. Profit after tax rose to Rs 26.56 crore, while net worth increased 20.15 per cent to Rs 160.07 crore. Earnings per share for the year stood at Rs 10.84.Divyam Rajesh Shah, Whole Time Director and CFO, Euro Panel Products, said the company’s..

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

Advertisement

Advertisement

-->